Rakuten Investment Management Inc. Invests $713,000 in Henry Schein, Inc. $HSIC

Rakuten Investment Management Inc. acquired a new position in Henry Schein, Inc. (NASDAQ:HSIC) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 10,749 shares of the company’s stock, valued at approximately $713,000.

Several other hedge funds have also recently added to or reduced their stakes in HSIC. Vanguard Personalized Indexing Management LLC grew its stake in shares of Henry Schein by 3.5% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 4,669 shares of the company’s stock worth $341,000 after purchasing an additional 157 shares in the last quarter. Equitable Trust Co. grew its position in Henry Schein by 3.1% in the 2nd quarter. Equitable Trust Co. now owns 5,317 shares of the company’s stock valued at $388,000 after buying an additional 158 shares in the last quarter. CW Advisors LLC increased its stake in Henry Schein by 2.8% during the 2nd quarter. CW Advisors LLC now owns 5,913 shares of the company’s stock valued at $432,000 after buying an additional 163 shares during the period. TD Asset Management Inc raised its position in shares of Henry Schein by 0.8% during the 2nd quarter. TD Asset Management Inc now owns 22,016 shares of the company’s stock worth $1,608,000 after buying an additional 164 shares in the last quarter. Finally, Simon Quick Advisors LLC raised its position in shares of Henry Schein by 5.5% during the 2nd quarter. Simon Quick Advisors LLC now owns 3,466 shares of the company’s stock worth $253,000 after buying an additional 182 shares in the last quarter. Institutional investors own 96.62% of the company’s stock.

Wall Street Analyst Weigh In

HSIC has been the topic of a number of research analyst reports. Barclays initiated coverage on shares of Henry Schein in a research note on Monday, December 8th. They set an “overweight” rating and a $86.00 price objective on the stock. Wall Street Zen upgraded Henry Schein from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Morgan Stanley lifted their price target on Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a research report on Wednesday, November 5th. Wells Fargo & Company boosted their price objective on Henry Schein from $70.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Finally, Mizuho set a $81.00 target price on Henry Schein and gave the company a “neutral” rating in a research note on Tuesday. Five equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $76.42.

Henry Schein Price Performance

NASDAQ HSIC opened at $77.21 on Friday. Henry Schein, Inc. has a 1 year low of $60.56 and a 1 year high of $82.49. The business’s fifty day moving average is $75.85 and its two-hundred day moving average is $70.67. The stock has a market capitalization of $9.09 billion, a P/E ratio of 24.43, a P/E/G ratio of 2.30 and a beta of 0.88. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.79 and a current ratio of 1.40.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, November 4th. The company reported $1.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.27 by $0.11. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%.The business had revenue of $3.34 billion for the quarter, compared to analysts’ expectations of $3.28 billion. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. On average, research analysts forecast that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.